<DOC>
	<DOC>NCT01768507</DOC>
	<brief_summary>Heme oxygenase 1 (HO-1) serves as a protective gene. The aim of this clinical trial is to evaluate the HO-1 stimulation of resveratrol in healthy humans.</brief_summary>
	<brief_title>Reresveratrol Administered to Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Resveratrol</mesh_term>
	<criteria>Signed informed consent prior to any studymandated procedure. Male patient aged between 18 and 45 years (inclusive) at screening. No clinically significant findings on the physical examination at screening. Body mass index (BMI) between 18 and 28 kg/m2 (inclusive) at screening. Nonsmoker (for at least 1 month) Hematology, clinical chemistry, and urinalysis test results not deviating from the normal range to a clinically relevant extent at screening. Negative results from urine drug screen at screening. Ability to communicate well with the investigator, in the local language, and to understand and comply with the requirements of the study. Known hypersensitivity to resveratrol or any excipients of the resveratrol formulation. Treatment with any investigational drug within 3 weeks prior to screening. History or clinical evidence of alcoholism or drug abuse within the 3year period prior to screening. History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of resveratrol. Smoker Previous treatment with any prescribed or OTC medications (including herbal medicines such as St John's Wort) within 2 weeks prior to screening. Regularly intake of resveratrol rich food Positive results from the hepatitis serology at screening. Positive results from the HIV serology at screening. Presumed noncompliance. Legal incapacity or limited legal capacity at screening.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>